Roxadustat Reduces the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting: a Multicenter, Randomized, Double-blind, Placebo-controlled Study
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Roxadustat (Primary)
- Indications Hypoxia; Ischaemia
- Focus Pharmacodynamics
- 06 Nov 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2021).
- 18 Apr 2022 Status changed from not yet recruiting to recruiting.
- 15 Sep 2021 Planned initiation date changed from 20 Aug 2021 to 30 Sep 2021.